CytomX Therapeutics Inc
CTMX3.570USD
+0.240+7.21%
收盘 10/31, 16:00（美东）报价延迟15分钟
588.73M总市值
12.27市盈率 TTM
关于 CytomX Therapeutics Inc 公司
CytomX Therapeutics, Inc. 是一家临床阶段、专注于肿瘤学的生物制药公司，致力于开发旨在定位于肿瘤微环境的新型条件激活生物制剂。该公司正在利用其 PROBODY 治疗技术平台推进潜在的同类首创和同类最佳抗体疗法。其产品线包括多种治疗方式的治疗候选药物，包括抗体-药物偶联物 (ADC)、T 细胞接合剂和免疫调节剂（如细胞因子）。其临床阶段产品线包括 CX-904、CX-2051 和 CX-801。CX-904 是一种条件激活的 T 细胞接合抗体，靶向肿瘤细胞上的表皮生长因子受体和 T 细胞上的 CD3 受体，并与安进公司建立了全球联合开发联盟。 CX-2051 是一种针对上皮细胞粘附分子 (EpCAM) 的条件激活 ADC，具有适用于多种表达 EpCAM 的上皮癌的潜在适用性。
CytomX Therapeutics Inc简介
公司代码CTMX
公司名称CytomX Therapeutics Inc
上市日期Oct 08, 2015
CEODr. Sean A. Mccarthy, Ph.D.
员工数量119
证券类型Ordinary Share
年结日Oct 08
公司地址151 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16505153185
网址https://cytomx.com/
公司代码CTMX
上市日期Oct 08, 2015
CEODr. Sean A. Mccarthy, Ph.D.
CytomX Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Ashworth, Ph.D.
Dr. Alan Ashworth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Robert (Jim) Meyers
Mr. James Robert (Jim) Meyers
Independent Director
Independent Director
--
--
Dr. Sean A. Mccarthy, Ph.D.
Dr. Sean A. Mccarthy, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
50.92M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月23日 周六
更新时间: 8月23日 周六
持股股东
股东类型
持股股东
持股股东
占比
VR Adviser, LLC
8.47%
Longitude Capital Management Co., LLC
7.00%
Tang Capital Management, LLC
6.71%
Perceptive Advisors LLC
5.87%
The Vanguard Group, Inc.
5.69%
其他
66.26%
持股股东
持股股东
占比
VR Adviser, LLC
8.47%
Longitude Capital Management Co., LLC
7.00%
Tang Capital Management, LLC
6.71%
Perceptive Advisors LLC
5.87%
The Vanguard Group, Inc.
5.69%
其他
66.26%
股东类型
持股股东
占比
Hedge Fund
31.85%
Venture Capital
20.65%
Investment Advisor
15.41%
Investment Advisor/Hedge Fund
11.30%
Private Equity
11.00%
Individual Investor
0.64%
Research Firm
0.24%
Corporation
0.23%
Pension Fund
0.14%
其他
8.53%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
190
149.41M
90.60%
+52.66M
2025Q2
174
79.06M
50.13%
+5.55M
2025Q1
180
46.88M
32.26%
-27.51M
2024Q4
187
47.68M
60.93%
-26.52M
2024Q3
193
52.18M
66.81%
-19.54M
2024Q2
203
57.59M
74.04%
-4.03M
2024Q1
239
45.58M
66.89%
-10.30M
2023Q4
245
33.58M
50.13%
-26.30M
2023Q3
276
33.60M
50.33%
-37.55M
2023Q2
290
35.13M
52.97%
-38.77M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
VR Adviser, LLC
13.97M
8.47%
+977.38K
+7.52%
Jun 30, 2025
Longitude Capital Management Co., LLC
11.54M
7%
+11.54M
--
May 13, 2025
Tang Capital Management, LLC
11.07M
6.71%
+4.35M
+64.72%
Jun 30, 2025
Perceptive Advisors LLC
9.68M
5.87%
+2.69M
+38.41%
Aug 14, 2025
The Vanguard Group, Inc.
9.38M
5.69%
+4.26M
+83.29%
Jun 30, 2025
Fidelity Management & Research Company LLC
8.66M
5.25%
+8.55M
+7898.03%
Jun 30, 2025
OrbiMed Advisors, LLC
8.46M
5.13%
+8.46M
--
Jun 30, 2025
Point72 Asset Management, L.P.
8.08M
4.9%
-5.01M
-38.26%
Jun 30, 2025
Commodore Capital LP
7.69M
4.66%
+7.69M
--
Jun 30, 2025
Franklin Advisers, Inc.
5.77M
3.5%
+5.77M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 20 小时前
更新时间: 20 小时前
机构名称
占比
Formidable ETF
2.19%
Inspire Fidelis Multi Factor ETF
1.65%
Invesco NASDAQ Future Gen 200 ETF
0.76%
First Trust Dow Jones Select MicroCap Index Fund
0.64%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
Formidable ETF
占比2.19%
Inspire Fidelis Multi Factor ETF
占比1.65%
Invesco NASDAQ Future Gen 200 ETF
占比0.76%
First Trust Dow Jones Select MicroCap Index Fund
占比0.64%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
